| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6070313 | Journal of the American Academy of Dermatology | 2015 | 11 Pages |
Abstract
The nevi associated with BRAF inhibitor therapy invariably lack BRAFV600E mutation. BRAF inhibition appears to cause an increased cytotoxic T-cell response and increased mitogen-activated protein kinase activity in BRAF wild-type lesions, supported by pERK expression, possibly resulting in an activated phenotype characterized by increased melanin pigmentation and deep HMB-45 expression.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Mark C. MD, Marc R. Hammond, Dennie T. Frederick, Maria B. MD, Adriano MD, Keith T. MD, Mai P. MD,